µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ `AWy!}8
4L8z>9D
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ B?+.2
9]"S:{KSCn
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ l0I}&,+
>D 97c|?c
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Ng\/)^
!)N|J$FU
1. CD4 yQ9ZhdQS
}.p<wCPy6
2. T cell receptor(TCR) Bs[nV}c>>
$f#a
gq_
3. immunoglobulin superfamily (IgSF) "< v\M85&
%?bcT[|3
4. selectin n-$VUo
"
Ya9~6
5. anti-idiotypic antibody (¦ÁId) ibJHU@l
7{f_fkbs
6. major histocompatibility complex(MHC) 6k"
P&AD
_d@=nK)
7. immunotolerance YzAFC11,
\hlR]m!C
8. biological reponse modifier(BRM) 0)|Q6*E>
;;Ds
9. immune reponse gene (Ir gene) [I l~K
Wkzs<y"
10. reshaped antibody (or reconstituted antibody) <YFY{VC(
?m0IehI
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© }CDk
9Xk
AW,OHSXh6
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ?":'O#E
la
<npX
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? :q#K} /
~u87H?
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ |J0Q,F]T
AoaN22
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? a
l&(-#1
RthT\%R
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) bEV<iZDq%
N_Akmh0D
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ gEQNs\Jn
L
SP]IUdE\
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? EGq;7l6u&?
hsKmnH@#
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? 9#d+RT
f:B>zp;N
¡¡ SLfFqc+n0
l`-bFmpA
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ h].~# *
y! .J
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨?
YXurYwV
Wo~vhv$E
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? .`<@m]m-
73#x|lY
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ h:zK(;
&!aAO(g
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ `LAR@a5i
-Y
Bd, k3
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ g,o?q:FL
iRg7*MQu
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© r:&`$8$
r<F hY
1. CD8 x8\A<(G_M=
2aJS{[
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 8Og_W8
~%?`P/.o
3. immunoglobulin fold(Ig fold) &E xYXI
V[-jD8='3
4. cadherin (Ca-dependent cell adhesion moleculers) p!k7C&]E
x(<(t:?o
5. idiotype-anti-idiotypic antibody immune network theory s"Pf+aTW
6[ OzU2nB
6. HLA class II antigen
/'31w9
5M9 I,
7. complementarity-determining region (CDR) Gmf B
J'N!Omz
8. perforin(or pore-forming protein ,PFP) j"AU z)x
!"8fdSfg
w
9. high affinity IL-2 receptor ?nP*\8
Sm~l:v0%
10. artificial active immunization x3PD1JUf
L#vI=GpL,r
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© &3yD_P_3
IpP~Uz
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠL[=a/|)TBV
>@"Oe
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ?JL:CBvCp
:O(^w}sle
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ d6
W SL;$
{'U
Rz[g
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ H<^/Ati,|
A'2w>8
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) Br`IW
f]`vRvbe
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ ^$t7+g
E8-P"`Qba
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? e@IA20
u;`U
*@
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Ntbg`LGf'!
!H ~<
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Z ,EvQ8i
"I
Ql Vi
¡¡ =KR
NvW
HQB(
*
;6!Pwb;hY
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ KG=h&
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ
7[.
6axL
8KR
ba4[
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ J.8IwN1E
q=#}
yEG
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 39=1f
6I1
>Bgw}PI
1. immunoglobulin gene rearrangement yUp,NfS]o
&cu lbcz
2. the common chain of cytokine receptor (or a cytokine receptor ]GRWnif
4!LCR}
K
subunit shared by some cytokine receptors) nG;8:f`
,L`$09\
3. flow cytometry(FCM) beu\cV3
#cCL.p"]
4. carrier effect EcCFbqS4W
L\#<JxY$p
5. positive selection of T lymphocytes in thymus X3V'Cy/sy
8f3vj
K'
6. mouse TH1(Th1) and TH2(Th2) subsets :at$HCaK
B}&x